Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alaunos Therapeutics, Inc.ZIOP · Entity 8339 | COO, CLO, and Secretary | December 29, 2017 | January 03, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alaunos Therapeutics, Inc.
Report date December 29, 2017 · Filed January 03, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 207,434 |
Ending reported balance
After 2017-12-31 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2017-12-29 · Grant · Acquired 87,000 · Balance 260,551 F1: 29,000 shares shall vest on each of 12/29/2018, 12/29/2019 and 12/29/2020. Row 2 · 2017-12-30 · Tax withholding · Disposed 31,450 · Balance 229,101 F2: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock grants. Row 3 · 2017-12-31 · Tax withholding · Disposed 21,667 · Balance 207,434 F2: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock grants. |
Filing footnotes · ownership attribution and instrument terms
F1: 29,000 shares shall vest on each of 12/29/2018, 12/29/2019 and 12/29/2020.
F2: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock grants.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 31, 2017 Filed Jan 3, 2018 21:51 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | Tax withholdingCommon Stock | 21,667 | $4.14 | $89,701.38 |
DisclosureSEC source: 0001209191-18-000972 · doc4.xml · nonDerivative · entry 3 BELBEL CAESAR J · CIK 0001109753 · COO, CLO, and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,434 F2 · shares: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock grants. Read SEC document |
| December 30, 2017 Filed Jan 3, 2018 21:51 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | Tax withholdingCommon Stock | 31,450 | $4.14 | $130,203.00 |
DisclosureSEC source: 0001209191-18-000972 · doc4.xml · nonDerivative · entry 2 BELBEL CAESAR J · CIK 0001109753 · COO, CLO, and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,101 F2 · shares: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock grants. Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 21:51 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantCommon Stock | 87,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-000972 · doc4.xml · nonDerivative · entry 1 BELBEL CAESAR J · CIK 0001109753 · COO, CLO, and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,551 F1 · shares: 29,000 shares shall vest on each of 12/29/2018, 12/29/2019 and 12/29/2020. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 20:31 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | Tax withholdingCommon Stock | 16,666 | $6.11 | $101,829.26 |
DisclosureSEC source: 0001209191-17-037731 · doc4.xml · nonDerivative · entry 1 BELBEL CAESAR J · CIK 0001109753 · COO, CLO, and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,551 F1 · shares: Represents shares withheld to satisfy withholding tax obligations upon the vesting of a restricted stock grant. Read SEC document |
| December 31, 2016 Filed Jan 4, 2017 21:39 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | Tax withholdingCommon Stock | 21,667 | $5.35 | $115,918.45 |
DisclosureSEC source: 0001209191-17-000982 · doc4.xml · nonDerivative · entry 2 BELBEL CAESAR J · CIK 0001109753 · COO, CLO, and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,217 F2 · shares: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock grants. Read SEC document |
| December 30, 2016 Filed Jan 4, 2017 21:39 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantCommon Stock | 94,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-000982 · doc4.xml · nonDerivative · entry 1 BELBEL CAESAR J · CIK 0001109753 · COO, CLO, and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,884 F1 · shares: 31,450 shares vest on each of 12/30/2017, 12/30/2018 and 12/30/2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.